Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy
February 20 2024 - 9:00AM
Business Wire
Omeros Corporation (Nasdaq: OMER) today announced the upcoming
presentation of a report detailing narsoplimab treatment in nine
adult patients with hematopoietic stem cell transplant-associated
thrombotic microangiopathy (TA-TMA). Narsoplimab is Omeros’
investigational antibody targeting MASP-2, the effector enzyme of
the lectin pathway of the complement system.
The report was authored by an external group of U.S.
investigators involved in the treatment of these patients with
narsoplimab provided under Omeros’ compassionate use program. It
will be featured as a poster presentation at the 2024 Tandem
Meetings – the Transplantation & Cellular Therapy Meetings of
the American Society for Transplantation and Cellular Therapy and
the Center for International Blood and Marrow Transplant Research,
to be held February 21-24, 2024 in San Antonio, Texas.
The poster will be presented by Lindsay Adkins, MSN, FNP-BC,
BMTCN, of the Sarah Cannon Transplant and Cellular Therapy Program,
Nashville, Tennessee. Details of the presentation are as
follows:
Real-World Experience with Narsoplimab
(OMS721) for the Treatment of Transplant-Associated Thrombotic
Microangiopathy (Poster #186) Poster Session: Acute
Regimen-Related Toxicity and Supportive Care Date: Thursday,
February 22, 2024 Presentation Time: 6:45 - 7:45 p.m. CST Location:
Exhibit Hall 4A
The presentation abstract is available now on the Tandem
Meetings website at the following link:
https://tandem.confex.com/tandem/2024/meetingapp.cgi/Paper/23952
The poster is expected to be made available on Omeros’ website
at www.investor.omeros.com shortly after the meeting
presentation.
About Omeros Corporation
Omeros is an innovative biopharmaceutical company committed to
discovering, developing and commercializing small-molecule and
protein therapeutics for large-market and orphan indications
targeting immunologic disorders including complement-mediated
diseases, cancers, and addictive and compulsive disorders. Omeros’
lead MASP-2 inhibitor narsoplimab targets the lectin pathway of
complement and is the subject of a BLA pending before FDA for the
treatment of hematopoietic stem cell transplant-associated
thrombotic microangiopathy. Omeros’ long-acting MASP-2 inhibitor
OMS1029 is currently in a Phase 1 clinical trial. OMS906, Omeros’
inhibitor of MASP-3, the key activator of the alternative pathway
of complement, is advancing in clinical programs for paroxysmal
nocturnal hemoglobinuria and complement 3 glomerulopathy. Funded by
the National Institute on Drug Abuse, Omeros’ lead inhibitor of
phosphodiesterase 7 OMS527 is in clinical development for the
treatment of cocaine use disorder and is also being developed as a
therapeutic for other addictions as well as for a major
complication of treatment for movement disorders. Omeros also is
advancing a broad portfolio of novel immuno-oncology programs
comprised of two cellular and three molecular platforms. For more
information about Omeros and its programs, visit
www.omeros.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, which are
subject to the “safe harbor” created by those sections for such
statements. All statements other than statements of historical fact
are forward-looking statements, which are often indicated by terms
such as “anticipate,” “believe,” “expect,” “intend,” and similar
expressions and variations thereof. Forward-looking statements,
including statements regarding Omeros’ investigational drug
candidates, anticipated next steps in relation to the BLA for
narsoplimab or in relation to other development programs are based
on management’s beliefs and assumptions and on information
available to management only as of the date of this press release.
Omeros’ actual results could differ materially from those
anticipated in these forward-looking statements for many reasons,
including, without limitation, unanticipated or unexpected outcomes
of regulatory processes in relevant jurisdictions, unproven
preclinical and clinical development activities, the Company’s
financial condition and results of operations, regulatory processes
and oversight, challenges associated with manufacture or supply of
our investigational or clinical products, intellectual property
claims, competitive developments, litigation, and the risks,
uncertainties and other factors described under the heading “Risk
Factors” in the company’s Annual Report on Form 10-K filed with the
Securities and Exchange Commission on March 13, 2023. Given these
risks, uncertainties and other factors, you should not place undue
reliance on these forward-looking statements, and the company
assumes no obligation to update these forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240220281063/en/
Jennifer Cook Williams Cook Williams Communications, Inc.
Investor and Media Relations IR@omeros.com
Omeros (NASDAQ:OMER)
Historical Stock Chart
From Mar 2024 to Apr 2024
Omeros (NASDAQ:OMER)
Historical Stock Chart
From Apr 2023 to Apr 2024